MorphoSys to Present at Five Upcoming Conferences

MorphoSys AG / MorphoSys to Present at Five Upcoming Conferences . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

ASCO (American Society of Clinical Oncology) Annual Meeting 2015
Date: May 29, 2015 - June 2, 2015
Venue: Chicago, IL, USA

Jefferies 2015 Global Health Care Conference
Date: June 3, 2015, 10:30am EDT (4:30pm CEST, 3:30pm BST)
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

Goldman Sachs 36th Annual Global Healthcare Conference
Date: June 10, 2015, 2:00pm PDT (11:00pm CEST, 10:00pm BST)
Venue: Rancho Palos Verdes, CA, USA
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

dbAccess German, Swiss & Austrian Conference
Date: June 17, 2015, 5:15pm CEST (4:15pm BST, 11:15am EDT)
Venue: Berlin, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

J.P. Morgan Cazenove European Healthcare Conference
Date: June 25, 2015
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG,
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR

A PDF version of all presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.